Metabolomics-Based Biosignatures of Prostate Cancer in Patients Following Radiotherapy.

Humans Male Mass Spectrometry Metabolomics / methods Phylogeny Prostatic Neoplasms / metabolism
biomarkers and diagnostics mass spectrometry parsimony phylogenetics prostate cancer radiotherapy untargeted (global) metabolomics

Journal

Omics : a journal of integrative biology
ISSN: 1557-8100
Titre abrégé: OMICS
Pays: United States
ID NLM: 101131135

Informations de publication

Date de publication:
04 2019
Historique:
entrez: 23 4 2019
pubmed: 23 4 2019
medline: 9 4 2020
Statut: ppublish

Résumé

Metabolomics offers new promise for research on prostate cancer (PCa) and its personalized treatment. Metabolomic profiling of radiation-treated PCa patients is particularly important to reveal their new metabolomic status, and evaluate the radiation effects. In addition, bioinformatics-integrated metabolomics-based approaches for disease profiling and assessment of therapy could help develop precision biomarkers in a context of PCa. We report mass spectrometry-based untargeted (global) serum metabolomics findings from patients with PCa (

Identifiants

DOI: 10.1089/omi.2019.0006 PMID: 31009330
pubmed: 31009330
doi: 10.1089/omi.2019.0006
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

214-223

Auteurs

Sinem Nalbantoglu (S)

1 Department of Biochemistry, Cellular and Molecular Biology, School of Medicine, Georgetown University, Washington, District of Columbia.
2 TUBITAK Marmara Research Center, Institute of Gene Engineering and Biotechnology, Molecular Oncology Laboratory, Gebze, Kocaeli, Turkey.

Mones Abu-Asab (M)

3 Section of Ultrastructural Biology, NEI/NIH, Bethesda, Maryland.

Simeng Suy (S)

4 Department of Radiation Oncology, School of Medicine, Georgetown University, Washington, District of Columbia.

Sean Collins (S)

4 Department of Radiation Oncology, School of Medicine, Georgetown University, Washington, District of Columbia.

Hakima Amri (H)

1 Department of Biochemistry, Cellular and Molecular Biology, School of Medicine, Georgetown University, Washington, District of Columbia.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Metabolomics-Based Biosignatures of Prostate...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Spectrométrie de masse › Metabolomics-Based Biosignatures of Prostate...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Métabolomique › Metabolomics-Based Biosignatures of Prostate...
questionsmedicales.fr › Sciences de l'information › Phylogenèse › Metabolomics-Based Biosignatures of Prostate...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Metabolomics-Based Biosignatures of Prostate...